Combo Therapy for Myelodysplastic Syndromes Misses Survival Goal in Randomized Trial

(MedPage Today) — HOUSTON — Survival in untreated, intermediate- and higher-risk myelodysplastic syndromes (MDS) failed to improve with the addition of the targeted agent venetoclax (Venclexta) to chemotherapy, a large randomized trial showed…

Source link : https://www.medpagetoday.com/meetingcoverage/soho/117342

Author :

Publish date : 2025-09-06 17:16:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30

Combo Therapy for Myelodysplastic Syndromes Misses Survival Goal in Randomized Trial

Are You Ready for Measles’ Wrath?

Who Needs a Beta-Blocker After a Heart Attack? RSV Vaccines and Hospitalizations

Related Posts

Complex Pancreatic Surgery Often Done at Low-Volume Centers

Preexisting Autoimmunity Tied to Better CAR T-Cell Outcomes

Bone Drug Fails to Stop Muscle Loss Post-Bariatric Surgery

Scientists discover why type 1 diabetes is worse in children

Fossil fuel emissions rise again – but China’s are levelling off

More Kids Have High Blood Pressure, Many May Be Missed by In-Office Screening Alone

Complex Pancreatic Surgery Often Done at Low-Volume Centers

Preexisting Autoimmunity Tied to Better CAR T-Cell Outcomes

Bone Drug Fails to Stop Muscle Loss Post-Bariatric Surgery

Scientists discover why type 1 diabetes is worse in children

Fossil fuel emissions rise again – but China’s are levelling off

More Kids Have High Blood Pressure, Many May Be Missed by In-Office Screening Alone

At Hush-Hush MAHA Summit, Vance Praises RFK Jr. for Defying Convention

Seladelpar Eases PBC-Related Itch for 30 Months

Categories

Archives